[
    {
        "file_name": "artaratherapeuticsinc_20200110_8-k_ex-10.5_11943350_ex-10.5_license agreement.pdf",
        "perturbation": [
            {
                "type": "Structural Flaws - Legal Contradiction",
                "original_text": "6.4 No Consequential Damages. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY UNDER THIS AGREEMENT IN A DIRECT ACTION BETWEEN THE PARTIES FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, LOSS OF PROFITS) SUFFERED BY THE OTHER PARTY.",
                "changed_text": "9.12 No Consequential Damages. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY UNDER THIS AGREEMENT IN A DIRECT ACTION BETWEEN THE PARTIES FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, LOSS OF PROFITS) SUFFERED BY THE OTHER PARTY.",
                "explanation": "Moving the 'No Consequential Damages' clause from the 'Representations; Indemnification' section to a new subsection within 'Miscellaneous' weakens its enforceability. Such clauses are standard in indemnity sections and less expected in miscellaneous sections.",
                "contradicted_law": "Legal precedent favoring enforceability of damage limitation clauses when clearly presented within the context of indemnity or liability.",
                "location": "Article 6 to Article 9"
            },
            {
                "type": "Structural Flaws - Legal Contradiction",
                "original_text": "5.4 Publication. The University and ArTara each agree to treat matters of authorship of the Publication in a proper collaborative spirit and following guidelines and policies in accordance with the University of Iowa’s Operations Manual which may be found at: https://opsmanual.uiowa.edu/.\nIt is anticipated that employees of the University will be first and senior authors on the Publication, but it is understood that final authorship will be determined in accordance with all applicable laws and regulations in publication practice, including Section 6002 of the Affordable Care Act a/k/a Sunshine Act and with ICMJE (International Committee of Medical Journal Editors) guidelines, standard scientific practice and journal guidelines.\nUniversity and/or Principal Investigator shall provide ArTara with a copy of any proposed Publication for review and comment at least […***…] prior to submission thereof for publication. ArTara shall have […***…], after receipt of said copy to object to such proposed Publication because there is Confidential Information which needs protection. In the event that ArTara makes such objection, University and/or Principal Investigator shall refrain from submitting such Publication for a maximum of […***…] from date of receipt of such objection in order for ArTara to file patent application(s) directed to patentable subject matter contained in the proposed Publication. If in its review, ArTara identifies information it considers to be its Confidential Information, ArTara may require redaction of that Confidential Information; provided, however, that ArTara shall not require removal of information necessary for complete and accurate presentation and interpretation of the Program Data and results. The Publication shall occur within […***…] of the date the Project is closed or terminated, or University and/or Principal Investigator shall be free to publish Program Data and results at that time.",
                "changed_text": "9.13 Publication. The University and ArTara each agree to treat matters of authorship of the Publication in a proper collaborative spirit and following guidelines and policies in accordance with the University of Iowa’s Operations Manual which may be found at: https://opsmanual.uiowa.edu/.\nIt is anticipated that employees of the University will be first and senior authors on the Publication, but it is understood that final authorship will be determined in accordance with all applicable laws and regulations in publication practice, including Section 6002 of the Affordable Care Act a/k/a Sunshine Act and with ICMJE (International Committee of Medical Journal Editors) guidelines, standard scientific practice and journal guidelines.\nUniversity and/or Principal Investigator shall provide ArTara with a copy of any proposed Publication for review and comment at least […***…] prior to submission thereof for publication. ArTara shall have […***…], after receipt of said copy to object to such proposed Publication because there is Confidential Information which needs protection. In the event that ArTara makes such objection, University and/or Principal Investigator shall refrain from submitting such Publication for a maximum of […***…] from date of receipt of such objection in order for ArTara to file patent application(s) directed to patentable subject matter contained in the proposed Publication. If in its review, ArTara identifies information it considers to be its Confidential Information, ArTara may require redaction of that Confidential Information; provided, however, that ArTara shall not require removal of information necessary for complete and accurate presentation and interpretation of the Program Data and results. The Publication shall occur within […***…] of the date the Project is closed or terminated, or University and/or Principal Investigator shall be free to publish Program Data and results at that time.",
                "explanation": "Moving the publication clause from the confidentiality section to the miscellaneous section. Terms regarding publications and restrictions on publication are better placed within the confidentiality constraints and moving to miscellaneous weaken the confidential nature.",
                "contradicted_law": "General legal principles surrounding confidentiality and trade secrets, where specific obligations are usually expected to be found in confidentiality sections.",
                "location": "Article 5 to Article 9"
            },
            {
                "type": "Structural Flaws - Legal Contradiction",
                "original_text": "7.1 ArTara, Affiliates, and sublicensees will obtain and maintain commercial general liability insurance with a reputable and financially secure insurance carrier prior to clinical testing, making, using, importing, offering to sell, or selling any licensed Product or engaging in any other act involving any licensed Product or the patent rights, if such act could possibly create risk of a claim against University Indemnitees for personal injury or property damage.\n(a) The insurance will identify University Indemnitees as additional insureds and will provide that the carrier will notify University in writing at least […***…] prior to cancellation, non-renewal, or material change in coverage. Should ArTara fail to obtain replacement insurance providing comparable coverage within such […***…] period, University will have the right to termination this Agreement effective as of the end of the […***…] period without notice or any additional cure period.\n(b) The insurance will include coverage for product liability with a minimum of […***…] dollars ($[…***…]) per occurrence and […\n***…] dollars ($[…***…]) annual aggregate, coverage for contractual liability, clinical trials liability if any such trial is performed,\nbodily injury and property damage, including completed operations, personal injury, coverage for contractual employees, blanket\ncontractual and products, and all other coverages standard for such policies. Such insurance will additionally include errors and\nomissions insurance with a minimum of […***…] dollars ($[…***…]) per occurrence.\n(c) Insurance policies purchased to comply with this Article Seven will be kept in force for at least […***…] after the last sale of licensed\nProduct.",
                "changed_text": "9.14 ArTara, Affiliates, and sublicensees will obtain and maintain commercial general liability insurance with a reputable and financially secure insurance carrier prior to clinical testing, making, using, importing, offering to sell, or selling any licensed Product or engaging in any other act involving any licensed Product or the patent rights, if such act could possibly create risk of a claim against University Indemnitees for personal injury or property damage.\n(a) The insurance will identify University Indemnitees as additional insureds and will provide that the carrier will notify University in writing at least […***…] prior to cancellation, non-renewal, or material change in coverage. Should ArTara fail to obtain replacement insurance providing comparable coverage within such […***…] period, University will have the right to termination this Agreement effective as of the end of the […***…] period without notice or any additional cure period.\n(b) The insurance will include coverage for product liability with a minimum of […***…] dollars ($[…***…]) per occurrence and […\n***…] dollars ($[…***…]) annual aggregate, coverage for contractual liability, clinical trials liability if any such trial is performed,\nbodily injury and property damage, including completed operations, personal injury, coverage for contractual employees, blanket\ncontractual and products, and all other coverages standard for such policies. Such insurance will additionally include errors and\nomissions insurance with a minimum of […***…] dollars ($[…***…]) per occurrence.\n(c) Insurance policies purchased to comply with this Article Seven will be kept in force for at least […***…] after the last sale of licensed\nProduct.",
                "explanation": "Moving the insurance requirement clause from the insurance section to the miscellaneous section. Moving the clause weakens the requirements associated to insurance",
                "contradicted_law": "General legal principles surrounding obligations in insurance sections",
                "location": "Article 7 to Article 9"
            }
        ]
    }
]